No exosome-based hair-loss product has FDA approval. Clinical trials in the USA are investigational; some operate under IND protocols or as commercial clinical studies outside the FDA formal pathway. European trials are registered but operate as investigational medical procedures. Regulatory pathways for cosmetic/medical classification remain unsettled; approval timelines are uncertain.
Androgenetic alopecia and other hair-loss conditions result from follicle miniaturisation, stem-cell exhaustion within the dermal papilla, and inflammatory signalling that disrupts the hair growth cycle. Exosomes derived from umbilical-cord fibroblasts and mesenchymal stem cells contain growth factors (bFGF, VEGF, HGF), microRNAs (miR-29b regulating collagen cross-linking), and lipid mediators that promote angiogenesis, collagen deposition, and hair-follicle neogenesis in preclinical models. Sixteen registered clinical trials and four actively recruiting studies assess topical, intradermal, and systemic exosome formulations alongside platelet-rich plasma and conventional minoxidil or finasteride regimens.
Съм ли кандидат? → · Hair Loss & Restoration: full overview → · Цена Косопад и възстановяване на косата → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка